Albiglutide
- Generic Name
- Albiglutide
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 782500-75-8
- Unique Ingredient Identifier
- 5E7U48495E
- Background
Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.
- Indication
用于2型糖尿病成年患者，作为饮食和运动的辅助疗法以改善血糖控制。不推荐用于饮食和运动控制不佳患者的一线治疗。
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2017-01-10
- Last Posted Date
- 2019-01-17
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03015519
- Locations
- 🇺🇸
GSK Investigational Site, El Paso, Texas, United States
An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects
- First Posted Date
- 2016-06-08
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4
- Registration Number
- NCT02793154
- Locations
- 🇺🇸
GSK Investigational Site, Dallas, Texas, United States
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 514
- Registration Number
- NCT02787551
- Locations
- 🇺🇸
Investigational Site Number 8400033, Baltimore, Maryland, United States
🇺🇸Investigational Site Number 8400079, Albany, New York, United States
🇺🇸Investigational Site Number 8400019, Columbus, Ohio, United States
Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2019-07-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8
- Registration Number
- NCT02750930
- Locations
- 🇺🇸
GSK Investigational Site, Shavano Prk, Texas, United States
Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2016-01-11
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02229240
Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 814
- Registration Number
- NCT02229227
- Locations
- 🇬🇧
GSK Investigational Site, Sidcup, United Kingdom
A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 374
- Registration Number
- NCT01777282
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.